BRAF and colonic neoplasm: In colon cancer patients, pharmaceutical antineoplastic expenditure in 2019 included monoclonal anti-EGFR antibodies (53.78%), anti-angiogenic agents (31.92%), BRAF-MEK inhibitors (7.35%), the multi-kinase inhibitor regorafenib (1.19%), and cytotoxic agents (4.57%).